Breast Neoplasm
Conditions
Keywords
18F-FAZA, 18F-FDG, Positron Emission Tomography, Cell Hypoxia
Brief summary
In about half the cases of breast cancer, there is hypoxic (no, or little oxygen) tissue present. Hypoxic cells can be resistant to treatment and may cause increased tumour growth. This study will use 18F-FAZA PET scans before surgery or treatment to assess whether patients have hypoxic tumours. The results will be compared to tissue samples removed during surgery and to the distribution of 18F-FDG.
Detailed description
Hypoxia or anoxia can be found in 50% of locally advanced breast carcinomas. Assessment of pre-treatment in viva and in vitro hypoxia could allow patient selection for more aggressive therapy or clinical trails focused on targeting hypoxia. We will use the PET radiotracer 18F-FAZA to monitor hypoxia in the protocol. We will study pathological characteristics on the final tumour restriction specimen and correlate prognostic and predictive factors with PET scan data. Tumour banking is optional.
Interventions
DRUG18F-FAZA PET scan
Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
DRUGFluGlucoScan Injection (18F-FDB) PET scan
Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
Sponsors
AHS Cancer Control Alberta
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female ≥ 18 years of age. If female of child bearing potential and if outside of the window of 10 days since the first day of the 0last menstrual period, patient will be required to have a negative pregnancy test. 2. Pathologically proven invasive duct carcinoma of the breast (FNA or core biopsy), T1-T4(T ≥ 1.5 cm) 3. FluGlucoScan Injection and 18F-FAZA PET scans performed prior to treatment. 4. FluGlucoScan Injection and 18F-FAZA PET scans performed within 4 weeks prior to their definitive surgery if subject does not have neoadjuvant therapy. 5. Able and willing to follow instructions and comply with the protocol 6. Provide written informed consent prior to participation in the study. 7. ECOG performance score ≤ 2
Exclusion criteria
1. Previous malignancy or diagnosis less than ten (10) years ago. Skin Cancers (excluding malignant melanoma) and carcinoma in situ of the cervix are exceptions. 2. Excisional biopsy of the primary breast tumour has been performed 3. Women with an invasive carcinoma of the breast that is not predominantly of the invasive duct subtype 4. Primary breast carcinoma previously treated. 5. Women who are nursing or pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uptake of 18F-FAZA (RUS and T/B) and its correlation to tumour size, auxiliary nodal status, tumour grade, EP/PR, and HER-2 status, Ki-67, Androgen receptor status (AR), vimentin and basal keratins, HIF-1 a and glomeruloid microvascular proliferation. | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| General biodistribution of 18F-FAZA and FluGlucoScan Injection | 5 years |
| Comparison of pre-operative 18F-FAZA and FluGlucoScan Injection PET images | 5 years |
Countries
Canada
Outcome results
None listed